<DOC>
	<DOCNO>NCT02694224</DOCNO>
	<brief_summary>To evaluate safety efficacy vismodegib standard neoadjuvant chemotherapy breast cancer patient base CTCAE v4 2010 1 . To study change biomarkers involve Hedgehog ( HH ) pathway first biopsy compare later one 2 . To detect predictive factor among patient reach pathological complete response ( pCR ) compare pCR 3 . To evaluate role addition vismodegib pCR rate 4 . To evaluate clinical response breast MRI rate breast conservative surgery neoadjuvant chemotherapy 5 . To evaluate QOL EORTC QLQ-C30 scale</brief_summary>
	<brief_title>Addition Vismodegib Neoadjuvant Chemotherapy Triple Negative Breast Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Triple Negative Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>1 . Female sex 2 . Ability give inform agreement carry whole study protocol study period 3 . The patient able carry need clinical trial measurable disease 4 . The patient 1875 yearold 5 . Triple negative breast cancer ( ER &lt; 1 % , Progesteron Receptor ( PR ) &lt; 1 % , nonoverexpressing HER2 ) . 1 . Patients oligometastatic disease ( 12 resectable metastasis ) could include 6 . No previous systemic therapy 7 . Patients go benefit neoadjuvant chemotherapy 8 . Eastern Cooperative Oncology Group ( ECOG ) &lt; 2 Karnofsky≥70 % 9 . Blood test biochemistry suitable : ( absolute neutrophil count &gt; 1500/uL ; haemoglobin &gt; 9 gr/dL ; platelet &gt; 100000/uL ( microliters ) ; total bilirubin≤ 1.5 upper normal limit ; GOT GPT ( transaminase ) ≤twice upper normal limit ; fast glucose≤150 gr/dL ; HbA1c≤8 % , serum creatinine≤2 mg/dL . 1 . Severe diseases infectious disease liver , kidney bone marrow failure advise participate study accord investigator criterion 2 . Pregnancy breast feeding period fertility woman agree contraception method 3 . Other primary tumor except breast situ carcinoma ( CIS ) , cervical neoplasia ( CIN ) localize skin tumor 4 . Inflammatory breast cancer bilateral breast cancer 5 . Bone fracture , peptic ulcus heal disorder 6 . Any local systemic therapy breast cancer 7 . To maintained immunosuppressant ( prednisone &gt; 10 mgr daily others ) , aspirin &gt; 325 mgr per day clopidogrel &gt; 75 mgr daily 8 . Cardiomyopathy New York Heart Association ( NYHA ) class IIIV ; heart stroke previous 6 month ; uncontrolled blood pressure ( systolic &gt; 150 mm Hg /or diastolic &gt; 100 mm Hg ) , coagulopathy hemorrhagic diseases 9 . Previous lung diseases 10 . Personal history abdominal perforation , abdominal abscess , abdominal fistula . 11 . Inability swallow pill 12 . Intolerance galactose , malabsorption galactose or/and glucose , primary hypolactasia</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>breast cancer</keyword>
	<keyword>triple negative</keyword>
	<keyword>neoadjuvant</keyword>
</DOC>